Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SSE:688505
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Operating Income
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SSE:688505
|
Operating Income
¥102.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥3.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
10%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥3.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Operating Income
¥787.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
See Also
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Operating Income?
Operating Income
102.3m
CNY
Based on the financial report for Dec 31, 2023, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Operating Income amounts to 102.3m CNY.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
2%
Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd have been -12% over the past three years , 2% over the past five years .